Compare State Street SPDR Bloomberg High Yield Bond ETF (JNK) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg High Yield Bond ETF vs TG Therapeutics Inc — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $92.84 (market cap $5.86B), while TG Therapeutics Inc trades at $55.24 (market cap $8.16B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, State Street SPDR Bloomberg High Yield Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg High Yield Bond ETF for 61 Days and TG Therapeutics Inc for 16 Days on average.
| JNK | TGTX | |
|---|---|---|
Market Cap | $5.86B | $8.16B |
Volume | 7,780,002 | 1,735,121 |
Sector | Fixed Income | Health |
52-Week High | $98.02 | $59.06 |
52-Week Low | $92.30 | $26.94 |
Typical Hold Time | 61 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JNK (SPDR Bloomberg High Yield Bond ETF) trades at $92.81 with minimal daily movement (+0.05%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The ETF maintains consistent dividend payments of $0.53 per share. Recent news highlights institutional interest with Envestnet Asset Management increasing its stake by 23.3% during the latest quarter.
The outlook for JNK is challenged by rising bond yields and macroeconomic uncertainty. While consistent dividends provide income appeal, the bearish technical setup and high-yield bond sensitivity to interest rate hikes present near-term risks. Institutional accumulation suggests long-term confidence, but investors should monitor credit market conditions closely.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
